4/28/2022

speaker
Conference Call Operator
Moderator

Greetings and welcome to Amaris' Q122 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Nick Moscato, Chief Strategy Officer. Please go ahead, sir.

speaker
Nick Moscato
Chief Strategy Officer

Thank you, Operator, and welcome to the Emeticis Investor Conference Call to discuss the results of the first quarter ended March 31st, 2022. A copy of our press release, supplemental slides, and related Form 8K filing with the SEC are available on the Investor Relations page of our website. Speaking on today's call from Emeticis will be President and Chief Executive Officer Chris Girard and Executive Vice President and Chief Financial Officer Scott Ginn. Also joining us is Dave Kimmerly, Chief Legal and Government Affairs Officer. Before we get started with our call, I would like to remind everyone that statements made on this conference call today may constitute forward-looking statements and are protected under the safe harbor of the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to Emeticis today. The company assumes no obligation to update information provided on this call to reflect subsequent events other than is required under applicable securities laws. These forward-looking statements may involve a number of risks and uncertainties, which may cause the company's results or actual outcomes to differ materially from such statements. These risks and uncertainties include factors detailed in our SEC filings, including our forms 10-K, 10-Q, and 8-K. In addition, as required by SEC Regulation G, A reconciliation of any non-GAAP measure mentioned during our call today to the most comparable GAAP measure will be available in our forms 10-K, 10-Q, and 8-K. Thank you, and now I'll turn the call over to President and CEO, Chris Girard.

speaker
Chris Girard
President and Chief Executive Officer

Chris Girard Thanks, Nick, and thanks to everyone for joining us. Today, Amedisys announced our first quarter 2022 results, which reflect the resilience of our core business, driven by our strategy that continues to differentiate us in our markets. Before we get into the performance update, I want to give a heartfelt thank you to all of our Medicis employees. These calls focus on important financial measures of our business, but I do not want to lose sight of what our people do daily. Our clinicians deliver the highest quality of care in the homes of the nation's most frail populations. These clinicians are aided by a fantastic support staff who enable them to focus on their efforts on delivering outstanding care to our patients. It is truly inspiring what you all do and I am sincerely thankful. The start of this year has been a hectic and exciting one. We saw Omicron disrupt our business as over 7% of our clinicians were on quarantine in January. We signed two home health acquisitions and are well on our way to additional inorganic growth. We saw discharge rates in our hospice business reach new highs We continue to feel tremendous amount of interest for hospital at home and other high acuity products. The competitive landscape continues to evolve as another large pair acquired assets in our space. And we recently saw the hospice proposed payment rule released. 2022 is off to a roaring start indeed. On the regulatory front, on March 30th, 2022, CMS issued the fiscal year 23 hospice payment rate update with the proposed 2.7% update to the hospice payments and corresponding increase to the hospice aggregate cap. This represents the fourth consecutive year where Medicare has increased hospice payments by at least 2%. In addition to the annual payment update, CMS is also proposing to place a 5% permanent cap on wage index decreases to smooth year-over-year changes in providers' wage indexes. We appreciate CMS's approach to hospital providers in this year's proposed rule, and we look forward to submitting our formal comments at the end of May. With that, let's jump into our segment performance, starting with home health. For the quarter, home health grew total admissions by 2%. As we mentioned during our last call, the Omicron wave that hit the U.S. in early January caused a record number of clinicians to be out on quarantine. which resulted in a lost volume of approximately 2,300 patients. Had we captured this volume, total volume growth for the quarter would have been 2%. Elective procedures, as a percent of our total episodes, has been volatile over the course of the first quarter. As the Omicron variant set in, we saw electives decline to 6.5% of total episodes as compared to 8.5% pre-pandemic. We have seen continued improvement in this number post-Omicron surge, and today electives make up about 7.4% of total episodes. For the quarter, we performed 13.0 visits per episode, down 0.7 visits sequentially, and down 0.9 visits year over year. Our implementation and utilization of MetaLogis continues to pay dividends as we continue to make progress optimizing the care we deliver to our patients while constantly focusing on improving our quality scores. On clinical mix, in Q1, we achieved 48% LPN utilization and 53% PTA utilization. We've made tremendous progress on our clinical mix and will continue to increase our utilization of both LPNs and PTAs throughout the year. Moving on to hospice. For the quarter, hospice same-story emits grew 2%, and ADC was down 3%. We ended the quarter with a hospice BD FTEs count of 514, which is down sequentially, and we have budgeted to grow to 550 by year-end. As we have discussed, we made great progress in 2021, ramping up our BD headcount after the anticipated turnover during the second quarter of last year. We are now going back and being more targeted in who we add and where we add them, making sure that our reps are producing and increasing their production as they grow their tenure. Hospice ADC remained pressured in Q1 as we continue to see a trend of patients coming onto service much later in the dying process and not realizing the full value of the benefit. In our 2022 guidance, we modeled a discharges as a percent of ADC rate that was higher than 2021, a year in which we saw new highs in discharges. In Q1, we saw higher than modeled discharge rates, but over the course of the last few weeks, we have seen this number moderate to levels that we had modeled. This trend is something we're constantly monitoring, and if the experience of the last month continues, you will see that translate into a better than expected ADC growth. To quantify the discharge rate, In January of 2020, discharges as a percent of ADC were 32.3% versus 39.1% in January of 2022. We have seen positive movement in this number and as of this call, April discharges as a percent of ADC is around 32%, which is below our internal expectations. The ADC impact from elevated discharge rate is approximately 170 ADC or 2.5 million for the quarter. Though we are behind on ADC, we continue to hold excess clinical capacity for when ADC returns. Our hospice discharge average length of stay fell to 89 days in Q1 from 90 days in Q4. And medium length of stay dropped to 21 days from 23 days. These decreases were driven by an increased percentage of deaths on census. Now I'd like to discuss Contessa's performance during the quarter. Contessa, our high acuity care segment, which specializes in home-based clinical programs for high acuity patients, continued its momentum from 2021 with a strong Q1 performance. While Contessa had two primary lines of business for the first quarter, With this hospital and SNF at home care models, it also launched a home-based palliative care model in the first quarter with Mount Sinai in New York, creating additional opportunity for the segment going forward. As a reminder, the hospital and SNF at home models have emissions that fall into two reimbursement categories, full risk and limited risk, with full risk being more favorable from a top-line revenue perspective. Total admissions in Q1 were 333, which was slightly behind expectations as we continue to integrate the business into our core operations. This integration is essential as it creates the infrastructure needed to recruit and retain nursing staff to accept patients referred to Contessa's programs. While meaningful progress has been made on the integration efforts related to nurse staffing, we continue to see a positive shift in reimbursement mix. as an increasing number of patients admitted into contested programs are full risk versus limited risk. I am also pleased to announce that we have deepened our partnership relationship with Mount Sinai Health System and reached a significant milestone as Mount Sinai contributed its home health agency in South Nassau to our existing joint venture for high acuity services. In addition to expanding the Mount Sinai partnership to include home health, Contessa also launched its first risk-based palliative care at home contract in New York with Medicare Advantage plan in late January. We are seeing early positive patient engagement trends in this program, which will be important beyond this partnership as we expand this business line to new geographies and contract structures that have increasing levels of financial risk. Through this transaction, and new service offering, our Mount Sinai partnership now offers a full continuum of home-based care that includes home health, hospital at home, SNF at home, and palliative care at home. This strategy is truly one of a kind in the industry and a major reason for why we see tremendous opportunity to capitalize on partnerships going forward as the only operator to provide an integrated home care offering. Moving on to operational performance. Contessa continues to demonstrate success in the clinical management of patients admitted into these programs. We again saw favorable MLR performance relative to expectations while keeping quality and satisfaction metrics at the forefront. Lastly, with respect to growth, we announced in February that Contessa closed another deal with yet another industry-leading health system in Virginia Mason Franciscan Health. This collaboration is an expansion of the existing common spirit joint venture partnership and will bring hospital level care into patients' homes in the Seattle, Tacoma, Washington market. HIPAA limitation is currently underway and the program Go Live is expected later this year. We also expect the Penn State Hershey partnership that we announced late in Q4 to launch toward the end of Q2 and remain confident in our ability to meet the goal of five new partnerships for 2022. In summary, I'm proud of the results we produced during the first quarter of this year. Each of our lines of business faced their own challenges, which forced us to think differently and innovatively about how we operate our business and deliver care. We remain acutely focused on doing all we can to enable our clinicians to be able to deliver the highest quality care and know that so long as we do that, financial results will follow as they did this quarter. Through the continued volatility in the marketplace, we delivered EBITDA ahead of our internal modeling and street consensus. We know we have work to do, are excited about what is in front of us, and look forward to besting our expectations. With that, I'll turn it over to Scott, who will take us through a more detailed review of our financial performance for the quarter.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-